L2 Acquisition of "Zhe" in Mandarin Chinese: A Corpus Study
Concentric Studies in Linguistics · 31.05.2015 · 41 (1) · 27-61
DOI: 10.6241/concentric.ling.41.1.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Concentric Studies in Linguistics, erschienen am 31.05.2015. Verfasst von Jen I. Li und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This paper examines the semantic and syntactic properties of the aspect marker -zhe in Mandarin Chinese as well as L2 adult learners' acquisition of -zhe using data from the Academia Sinica corpus and a learner corpus compiled by the Mandarin Training Center at National Taiwan Normal University. -Zhe sentences were categorized into three major patterns - V-zhe, V_1-zhe-V_2, and V_1-zhe-V_1-zhe-(jiu-)V_2, with each further divided into sub-types. Major findings were: (a) Usage of the various types of -zhe produced by the highest proficiency level learners in the corpus was closest to that of native speakers'. (b) The rate of V-zhe occurrence increased with the learners' proficiency level. (c) The rate of V_1-zhe-V_1-zhe-(jiu-)V_2 occurrence decreased with the learners' proficiency level. Error analysis revealed additional insights. These findings suggest that L2 teaching of Mandarin must take the various patterns of -zhe and the semantic and syntactic properties of the verbs occurring with -zhe into consideration.
Schlagwörter
Zitieren
APA
Li, J. I., & Hsieh, M. (2015). L2 Acquisition of "Zhe" in Mandarin Chinese: A Corpus Study. Concentric Studies in Linguistics, 41(1), 27-61. https://doi.org/10.6241/concentric.ling.41.1.02
Vancouver
Li JI, Hsieh M. L2 Acquisition of "Zhe" in Mandarin Chinese: A Corpus Study. Concentric Studies in Linguistics. 2015;41(1):27-61. doi:10.6241/concentric.ling.41.1.02
BibTeX
@article{Li2015,
author = {Li, Jen I. and Hsieh, Miao-Ling},
title = {L2 Acquisition of "Zhe" in Mandarin Chinese: A Corpus Study},
journal = {Concentric Studies in Linguistics},
year = {2015},
volume = {41},
number = {1},
pages = {27--61},
doi = {10.6241/concentric.ling.41.1.02}
}
EUVIMED